Join the Society for FREE Today!
SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.
SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies.
Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.
The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. The fourteenth annual meeting of the Society of Hematologic Oncology (SOHO 2026) is scheduled for September 9-12, 2026 at the GRB Convention Center in Houston, Texas. As a hybrid event, SOHO 2026 offers in-person, virtual and on-demand participation.
The Ambassador program was created to increase geographical diversity
promote international understanding among hematologic oncology experts around the world.
promote international understanding among
hematologic oncology experts around the world.
If you are interested Contact Us!
The speakers highlighted how combining these powerful drugs into fixed-duration regimens could help patients achieve long-term remissions and move closer to a cure.
The panel also discussed the success of combining teclistamab and daratumumab for functional high-risk patients who historically experience poor outcomes.
The panel also discussed the therapeutic potential of these combinations. Dr. Banerjee highlighted the role of CELMoDs in post-CAR T care, noting that “if you find a drug that’s well-tolerated, like a cell mod, that may be what you need to keep those
The panel discussed combining trispecifics with mezigdomide, noting the strong activity and improved tolerability of targeting BCMA and CD38. They also discussed how mezigdomide might reverse T-cell exhaustion, while cautioning that careful treatment